I don't know if you are aware they have a positive Phase 3 study already. I don't think they would get combo use in their label obviously and I don't see great commercial prospects as montherapy with their (inferior) efficacy and (likely) much higher cost. So basically they have one positive study which is highly significant (though I believe slightly above .01) using the same drug that is already approved in 3 other forms (IV, Sub-q and inhaled) and two additional trials that while not significant trend and provide safety data. In orphan indications with one positive trial and < .01 significance there are numerous precedence for approval. So I wouldn't rule out an approval at all.
I wouldn't sell at these prices but I would only cosider buying again somewhere below 30 myself (though it may never get there).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.